CDK1 and ovarian carcinoma: Interestingly, NSC777201 demonstrated anti-proliferative and cytotoxic activities (GI50 = 1.6 μM~1.82 μM and TGI50 = 3.5 μM~3.63 μM) against the NCI panels of ovarian cancer cell lines and exhibited a robust interaction with stronger affinities for TTK, NEK2, and CDK1, than do the standard drug, paclitaxel.